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Summary We present a 4-year fol low-up of a 42-year- 
old patient with pr imary thrombocythemia whose clini- 
cal course was complicated by two major mucocuta- 
neous bleeding episodes. On both occasions an ac- 
quired functional yon Wil lebrand factor deficiency was 
demonstrated. In contrast o what is reported in the lit- 
erature, an inverse relationship between platelet num- 
ber and plasma high-molecular-weight multimers of 
von Wil lebrand factor was established. 
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Introduction 
Primary thrombocythemia (PT), a clonal myeloprol i fer- 
ative disorder characterized by a persistent elevation of 
the platelet count, paradoxical ly predisposes to both 
thrombosis and hemorrhages [13, 15]. Despite the iden- 
tification of a broad array of specific structural, bio- 
chemical, and metabol ic platelet defects in patients 
with PT, a convincing correlation between these defects 
and the clinical complications of thrombosis and bleed- 
ing has never been established [13, 15]. 
Several authors have described a decrease or ab- 
sence of plasma high-molecular-weight multimers of 
yon Wil lebrand factor (vWF) in patients with myelo- 
proliferative disorders and associated bleeding tenden- 
cy [4, 5, 10]. We present here a 4-year fol low-up of a 
patient with PT whose clinical course was complicated 
by two bleeding episodes associated with an acquired 
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von Wil lebrand factor deficiency. An  inverse relation- 
ship between platelet number  and plasma high-molecu- 
lar-weight multimers of von Wil lebrand factor was de- 
monstrated. 
Case report 
A 42-year-old woman was referred to our department in Decem- 
ber 1989 with upper abdominal complaints due to massive sple- 
nomegaly. Ultrasound examination of the abdomen revealed an 
enlarged spleen of 20 cm and thrombosis of the splenic vein. Sub- 
sequent endoscopy showed esophageal varices. A slight thrombo- 
cytosis of 431 x 109 platelets per liter was established (Fig. 1). He- 
moglobin levels, white cell count and differentiation, creatinine, 
urea, and liver function tests were all normal. Extended hemos- 
tatic analysis excluded the presence of a lupus anticoagulant anti- 
body and a deficiency of antithrombin III, protein C, and protein 
S. Bone marrow smear and biopsy material showed an increased 
cellularity of normal hematopoiesis, a pronounced increase of 
clustered megakaryocytes, and the presence of fine reticulin fi- 
bers, but the absence of collagen fibers and osteosclerosis, compa- 
tible with the diagnosis of PT [15]. The score for the leukocyte 
alkaline phosphatase tain was 129 (normal 20-100 U/ml). Splen- 
ectomy in December 1989 (spleen weight 788 g) was uneventful. 
In March 1990, the platelet count rose to about 3500 x 109/1; this 
was associated with spontaneous mucocutaneous bleeding con- 
sisting of easy bruising, recurrent ecchymoses after minor injuries, 
and melena, causing a fall of the hemoglobin level from 7.3 to 4.6 
mmol/1. Extended coagulation tests revealed a functional defi- 
ciency of plasma von Willebrand factor [yon Willebrand factor 
antigen (vWF:Ag) 1.36 U/ml; ristocetin co-factor activity 
(vWF: RCoF) 0.40 U/ml, and collagen binding activity 
(vWF:CBA) 0.22 U/ml, normal values for all vWF-related activi- 
ties 0.60-1.40 U/ml)] and a prolonged Ivy bleeding time (> 15 
rain; normal _< 4 min). Platelet aggregation tests were normal. 
From that time on we prospectively studied plasma von Wille- 
brand factor activities in relation to the platelet count. Reduction 
of the platelet count with hydroxyurea resulted in disappearance 
of the bleeding symptoms and the functional yon Willebrand fac- 
tor defect and in a normalization of the Ivy bleeding time. At 
platelet counts between 700 and 1650 x 109/1 for more than 1 year 
neither the bleeding nor the functional von Willebrand factor de- 
fect (vWF:Ag varied from 1.22 to 2.00 U/ml; vWF:RCoF from 
0.64 to 1.72 U/ml, and vWF: CBA from 0.67 to 1.26 U/ml) recur- 
red. 
Discontinuation of hydroxyurea because of side effects (head- 
ache and nausea) in August 1992 resulted in a rapid increase in 
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Fig. 1 The clinical course of a patient with primary thrombocy- 
themia was complicated by two mucocutaneous bleeding episodes 
at platelet counts above 2000 x 109/1. On both occasions a func- 
tional von Willebrand factor deficiency was demonstrated; this 
disappeared after reduction of the platelet count with hydroxyur- 
ea. Von Willebrand factor activities are expressed as the ratio of 
either vWF: RCoF/vWF: Ag or vWF: CBA/vWF: Ag to denote 
the amount of functionally active von Willebrand factor. The up- 
per two horizontal lines represent he normal range for the 
vWF: RCoF/vWF: Ag and vWF: CBA/vWF: Ag ratios. The lower 
two horizontal ines indicate the normal range for the platelet 
count 
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wells were incubated with 1/200 dilution in PBS-Tween-albumin 
of horseradish peroxidase-conjugated rabbit polyclonal immuno- 
globulins to human vWF (Dakopatts, Denmark) for another 2 h 
at room temperature. After washing, 100 Ixl ABTS substrate solu- 
tion was added. After 15 min incubation the color development 
was stopped by the addition of 10 ixl concentrated acetic acid and 
the extinction was measured at 414 nm. The multimeric pattern of 
vWF was visualized according to Brosstad et al. [2]. 
The relationship between platelet count and plasma levels of 
von Willebrand factor was analyzed by linear regression and 
Spearman's rank correlation test. Statistical significance was ac- 
cepted at p < 0.05. 
circulating platelets (platelet counts 3700-4000 x 109/1) and recur- 
rence of the mucocutaneous bleeding tendency, which was char- 
acterized by easy bruising, prolonged bleeding after minor cuts, 
and menorrhagia, causing a fall of the hemoglobin level from 7.0 
to 3.7 mmol/1. Again, a functional von Willebrand factor defect 
(vWF:Ag 1.31 U/ml; vWF:RCoF 0.46 U/ml, and vWF: CBA 0.11 
U/ml) and a prolongation of the bleeding time (> 15 min) were 
demonstrated. The bleeding symptoms and the functional von 
Willebrand factor defect disappeared after reduction of the plate- 
let count with hydroxyurea. The hemoglobin level completely re- 
covered with oral iron administration. 
Material and methods 
All hemostatic tests were performed using routine procedures. 
Platelets were counted electronically in blood anticoagulated with 
EDTA. Bleeding times were measured according to Ivy et al. [9]. 
Von Willebrand factor antigen was assayed by an ELISA using 
rabbit anti-human vWF and rabbit horseradish peroxidase-conju- 
gated anti-human vWF polyclonal antibodies [7]. Ristocetin co- 
factor activity was assayed with formalin-fixed platelets [11] (in- 
tra-assay variation 10%; inter-assay variation 11%). The binding 
of vWF to collagen was measured according to the ELISA-based 
method of Brown and Bosak [3], with slight modifications (intra- 
assay variation 5%, inter-assay variation 9%). Microtiter plate 
wells (A/S Nunc, Roskilde, Denmark) were coated overnight at 
4~ with 100 ~1 of a 0.2-mg/ml suspension of collagen (bovine 
achilles tendon, type I, Sigma, St. Louis, USA) in 20 mM acetic 
acid. After washing with PBS-Tween, 100 txl of a 1/40 dilution of 
the test plasmas in PBS-Tween-albumin were added to the wells 
and incubated for 2 h at room temperature. After rinsing, the 
Results 
The clinical course of the descr ibed pat ient  was compli -  
cated by two major  b leeding events. On both occasions 
an acquired von Wi l lebrand defect and a pro longed Ivy 
b leeding t ime were demonstrated,  occurr ing at p late let  
counts above 2000 x 109/1 (Fig. 1). A t  t imes of manifest  
b leeding,  the vWF:  RCoF/vWF:  Ag  rat ios and 
vWF:  CBA/vWF:  Ag  ratios were decreased at 
0.40+0.13 and 0.19_+0.08, respectively,  indicat ing a 
funct ional  def ic iency of vWF.  Reduct ion  of the p late let  
count with hydroxyurea  resulted in d isappearance of 
the b leeding symptoms as well  as of the acquired func- 
t ional von Wi l lebrand defect (Fig. 1) and in a normal i -  
zat ion of the Ivy b leeding time. A signif icant inverse 
re lat ionship between the p late let  count and the rat ios 
of vWF:RCoF/vWF:Ag ( r=-0 .728 ,  p<0.001)  and 
vWF:CBA/vWF:Ag ( r=-0 .834 ,  p<0.001)  was de- 
monst ra ted  (Fig. 2). Analys is  of the vWF mult imers  at 
di f ferent levels of thrombocytos is  (Fig. 3) revea led a 
progressive decrease of the h igh-molecular -weight  mul- 
t imers of vWF with increasing p late let  counts. 
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Fig. 2 Intrapatient relationship between platelet count and either 
vWF:RCoF/vWF:Ag ratio (open symbols) or vWF:CBA/ 
vWF:Ag ratio (closed symbols) and corresponding linear curve 
fits (broken and solid lines, respectively) 
l~g. 3 Multimeric pattern of plasma von Willebrand factor of 
normal pooled plasma and patient's plasma at different levels of 
thrombocytosis. Lane 1, normal pooled plasma; lane 2-6, multim- 
eric pattern ofplasma vWF of the patient at platelet 4 counts of 
9 9 9 390 x 109/1, 727 • 109/1, 1058 x10 /1, 2905 x10 /1, and 3938 x 10/l, 
respectively. Note the progressive decrease of high-molecular- 
weight multimers of von Willebrand factor in the plasma of the 
patient with increasing platelet counts 
Discussion 
In the reported patients with PT and an acquired von 
Willebrand factor deficiency, bleeding usually became 
apparent at platelet counts in excess of 1000 x 109/1 and 
disappeared or improved after reduction of the platelet 
count to below 1000 x 109/1, suggesting that platelets 
play a pivotal role in the etiology of such bleeding [4, 5, 
10]. However, a clear relationship between platelet 
count and clinical complication of bleeding has never 
been established [13, 15]. 
In the patient presented here an inverse relationship 
between platelet number and plasma vWF was demon- 
strated, resulting in a functional von Willebrand factor 
defect at platelet counts above 1000x109/1. With in- 
creasing platelet counts both the vWF:RCoF/vWF:Ag 
and vWF: CBA/vWF:Ag ratios progressively de- 
creased, suggesting a deficiency of the high-molecular- 
weight multimers of vWF, the most potent forms of 
vWF in securing hemostasis. The decrease of high-mo- 
lecular-weight multimers of vWF at platelet counts 
above 1000 x 109/1 was also demonstrated by visualiza- 
tion of the multimeric distribution of vWF. However, 
clinical bleeding became manifest only at platelet 
counts in excess of 2000 x 109/1. Laboratory investiga- 
tions at times of bleeding showed a deficiency of 
vWF: CBA activity, in contrast to nly subnormal val- 
ues of vWF:RCoF activity, suggesting that the 
vWF: CBA activity is a more reliable parameter of in 
vivo vWF function than the ristocetin co-factor activi- 
ty. 
This report and previous studies [4, 5, 10] indicate 
that cytoreduction of the platelet count below 
1000x109/1 favors prevention of bleeding complica- 
tions in PT, which is consistent with recent epidemio- 
logical findings that hemorrhages in PT occur more fre- 
quently at platelet counts in excess of 1000 x 109/1 [1, 8, 
15, 16]. However, in patients with reactive thrombocy- 
tosis hemorrhagic omplications occur rarely or not at 
all, which suggests that more than a rise in the number 
of circulating platelets is needed to explain the ob- 
served hemorrhagic predisposition i primary thrombo- 
cythemia [13, 15]. 
The pathogenesis of the von Willebrand factor defi- 
ciency in PT is unclear. It has been demonstrated that 
the deficiency of the high-molecular-weight multimers 
of vWF is a phenomenon occurring in vivo and is not 
due to proteolysis in vitro [5, 14]. The observed in- 
crease in proteolytic leavage fragments of the vWF 
subunit in PT might be attributed to in vivo degrada- 
tion of von Willebrand factor by platelet-derived cal- 
cium-activated neutral proteases (calpains) and human 
leukocyte lastase [5]. However, others suggest that the 
decrease of the high-molecular-weight multimers of 
vWF is the result of binding of vWF to an increased 
number of circulating activated platelets a  high platelet 
counts [12, 14]. Although the exact mechanism opera- 
tive in PT remains to be determined, our data imply 
that the decrease of the high-molecular-weight multim- 
ers of von Willebrand factor is related to an elevated 
number of circulating platelets. Interestingly, Budde 
and colleagues [6] have recently shown that the de- 
crease of the high-molecular-weight multimers of von 
Willebrand factor is also demonstrable in the plasma of 
patients with reactive thrombocytosis. Therefore, an el- 
evated number of circulating platelets is more likely to 
be responsible for the observed ecrease in high-molec- 
ular-weight multimers of von Willebrand factor than 
the presence of presumed functionally abnormal plate- 
lets derived from clonal proliferation. However, further 
studies of larger patient groups are indicated to clarify 
the correlation of vWF abnormalities and the occur- 
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rence of a b leeding tendency in the course of myelo-  
prol i ferat ive disorders,  as is evident f rom the presented 
case, whereas such a corre lat ion has not been docu- 
mented  in pat ients with reactive thrombocytos is .  
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